Motley Fool Article - sangamo HIV mention

http://www.fool.com/investing/general/2015/05/21/following-hepatitis-c-this-could-be-the-next-disea.aspx

The researchers at Sangamo BioSciences (NASDAQ:SGMO) hope that they may be able to functionally cure HIV patients one day.

Source: GlaxoSmithKline via Facebook.

The company is using their zinc finger therapeutic approach to modify a key gene receptor known as CCR5 that plays a critical role in HIV's ability to infect T-cells in the immune system. If Sangamo is able to effectively shut down HIV's ability to spread by targeting CCR5, then it could revolutionize patient treatment. Currently, HIV is treated with an array of pills that must be taken daily for the rest of a patient's life and that can cause a bevy of side effects.
In February, researchers presented data showing that Sangamo's SB-728-T reduced viral load below the limit of quantification in one out of three patients. If that can be duplicated or improved upon in larger, later stage trials, then Sangamo could end up delivering on its promise of a potential cure to HIV. However, before we get too excited about this possibility, we need to realize that Sangamo's research remains in the early stages, so it will be a while before we know for certain whether or not this approach will work.